Evaluation of WO2013076170: the use of a dihydroorotate dehydrogenase inhibitor for the treatment of psoriasis

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.23, Iss.10, 2013-10, pp. : 1391-1394

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacophore-Based Discovery of New Human Dihydroorotate Dehydrogenase Inhibitor

Medicinal Chemistry, Vol. 10, Iss. 4, 2014-04 ,pp. : 402-408

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of dihydroorotate dehydrogenase

By Batt D.G.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 1, 1999-01 ,pp. : 41-54

Informa Healthcare

Access to resources Recommend Favorite

Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569

By Wolf Joel Ferris Laura Korb

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 4, 2014-04 ,pp. : 477-479

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2013116562A, an orally active PI3Kδ inhibitor for the treatment of asthma

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 5, 2014-05 ,pp. : 603-607

Informa Healthcare

Access to resources Recommend Favorite

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide

By Pawlik Andrzej Herczynska Magdalena Kurzawski Mateusz Safranow Krzysztof Dziedziejko Violetta Drozdzik Marek

Pharmacogenomics, Vol. 10, Iss. 2, 2009-02 ,pp. : 303-309

Future Medicine

Access to resources Recommend Favorite